Research programme: ubiquitin ligases - Synaptic Research
Latest Information Update: 01 Aug 2016
At a glance
- Originator Synaptic Research
- Class Antibacterials
- Mechanism of Action Botulinum toxin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Botulism
Most Recent Events
- 01 Aug 2016 Early research in Botulism in USA (unspecified route)